Cullinan Oncology(US:CGEM) Globenewswire·2026-01-08 12:00Core Insights - Cullinan Therapeutics is advancing multiple clinical programs in autoimmune diseases and cancer, with significant data readouts expected in 2026 [1][2][3] Group 1: Autoimmune Programs - The company has made progress with CLN-978, completing multiple dose cohorts in OUTRACE RA and OUTRACE SLE studies, and has initiated dosing in the Sjögren's disease study [2] - Initial data from the single target dose escalation for OUTRACE RA and OUTRACE SLE is expected in Q2 2026, focusing on safety and B cell depletion [4] - Repeat dosing data for OUTRACE RA is anticipated in Q3 2026, while initial data for OUTRACE SjD is expected in Q4 2026 [4][5] Group 2: Oncology Programs - The CLN-049 program is progressing with plans to complete dose expansion cohorts for relapsed/refractory AML and TP53m AML in Q2 2026, and to initiate a frontline combination study in Q4 2026 [3][11] - Zipalertinib's rolling NDA submission is expected to be completed in Q1 2026, with full enrollment of the REZILIENT3 frontline study anticipated in H1 2026 [1][11] Group 3: Financial Position - As of December 31, 2025, the company reported preliminary cash and investments of $439.0 million, providing a runway into 2029 under its current operating plan [1][8]